Hypotension News and Research

RSS

Study of Rituxan (rituximab) in lupus nephritis misses primary endpoint

Genentech, Inc. and Biogen Idec has announced that a Phase III study of Rituxan (rituximab) plus mycophenolate mofetil (MMF) and corticosteroids in patients with lupus nephritis did not meet its primary endpoint of significantly reducing disease activity at 52 weeks.

11 Mar 2009

Lilly receives complete response letter for Olanzapine LAI for treatment of schizophrenia

Eli Lilly and Company has announced that it received a complete response letter from the U.S. Food and Drug Administration (FDA) for olanzapine long-acting injection (LAI) for acute and maintenance treatment of schizophrenia in adults.

7 Jan 2009

FDA approves Lusedra (fospropofol disodium) injection for monitored anesthesia care sedation

Eisai Corporation of North America today announced that the U.S. Food and Drug Administration (FDA) has approved Lusedra (fospropofol disodium) Injection, an intravenous sedative-hypnotic agent for monitored anesthesia care (MAC) sedation in adult patients undergoing diagnostic or therapeutic procedures.

14 Dec 2008

Use of rapid response team in hospital not linked with reduction in cardio arrests or deaths

Although there is an effort to implement rapid response teams in hospitals throughout the country, new research suggests that they do not result in a reduced rate of cardiopulmonary arrests or deaths, according to a study in the December 3 issue of JAMA.

3 Dec 2008

FDA approves tapentadol immediate-release tablets for pain in adults

Millions of Americans with moderate to severe acute pain and their health-care providers will soon have a new treatment option.

21 Nov 2008

Link between dementia and hypotension - Alzheimer's sufferers might have lower blood pressure

A new study published in Bioscience Hypotheses, a recently launched Elsevier journal, proposes that some people suffering from Alzheimer's disease experience a reduction in their high blood pressure because of cognitive decline.

14 Oct 2008

Why sufferers from Alzheimer's disease might have lower blood pressure

A new study published in Bioscience Hypotheses, a recently launched Elsevier journal, proposes that some people suffering from Alzheimer’s disease experience a reduction in their high blood pressure because of cognitive decline.

14 Oct 2008

FDA approves Rapaflo for treatment of symptoms due to benign prostatic hyperplasia

The U.S. Food and Drug Administration today approved Rapaflo (silodosin) capsules for the treatment of symptoms due to benign prostatic hyperplasia (BPH), a condition also known as an enlarged prostate.

12 Oct 2008

New biomarkers in acute cardiac care

In conjunction with clinical assessment and the ECG, simple and rapid blood tests have become the standard for the detection of myocardial infarction. Starting in the year 2000, recommendations by the European Society of Cardiology and other major cardiology societies worldwide have begun to state uniformly that a rise in cardiac troponins - sensitive and specific markers for dying cells in the heart - is a prerequisite for the clinical diagnosis of myocardial infarction.

1 Sep 2008

Beta blockers after surgery more risky than beneficial

The results of new research has shown that patients given high doses of beta blocker drugs following non-cardiac surgery were more likely to have a stroke or die. However they were less likely to suffer a heart attack.

13 May 2008

Nurse care for schizophrenia patients

Drug and psychosocial interventions for the symptoms of schizophrenic disorders contribute to a lower incidence and prevalence of schizophrenia. Nurses will be able to offer better care through the use of nursing models and theories in the care of Schizophrenics.

6 May 2008

New research suggests hypertonic, hyperviscous fluids may be better treatment for severe blood loss

Intravenous administration of isotonic fluids is the standard emergency treatment in the U.S. for patients with severe blood loss, but UC San Diego bioengineering researchers have reported improved resuscitation with a radically different approach. Building on earlier studies in humans that have shown benefits of intravenous fluids that are eight times saltier than normal saline, the researchers combined hypertonic saline with viscosity enhancers that thicken blood.

29 Apr 2008

Stroke pilot study results to be announced at University of Leicester

Preliminary results from a major multi-centre UK pilot trial into Stroke are to be announced at the University of Leicester on 22 April.

21 Apr 2008

New blood pressure drug telmisartan has fewer side effects

A major Canadian-led global study has found that a new blood pressure medication is effective in reducing cardiovascular death, with fewer side effects than the current standard of care.

1 Apr 2008

Naglazyme approved in Japan

BioMarin Pharmaceutical Inc. has announced that AnGes MG, Inc. (AnGes), BioMarin's marketing and distribution partner in Japan, has received approval for its Marketing Application for Naglazyme(R) (galsulfase) from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the treatment of patients with Mucopolysaccharidosis VI ( MPS VI).

1 Apr 2008

AstraZeneca submits sNDA for SEROQUEL XR for treatment of major depressive disorder

AstraZeneca has announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for once- daily SEROQUEL XR (quetiapine fumarate) Extended-Release Tablets to seek approval for the treatment of major depressive disorder (MDD) as monotherapy, adjunct therapy, and maintenance therapy in adult patients.

1 Mar 2008

Lilly knocked back by FDA on Zyprexa for schizophrenia treatment

Eli Lilly and Company has received a not approvable letter from the U.S. Food and Drug Administration for Zyprexa long-acting injection (olanzapine LAI) for the treatment and maintenance treatment of schizophrenia in adults, the company announced.

28 Feb 2008

XYNTHA approved for teatment of hemophilia A by FDA

Wyeth Pharmaceuticals, a division of Wyeth ( NYSE:WYE) , announced today that it has received approval from the U.S. Food and Drug Administration for XYNTHA(TM) (Antihemophilic Factor [Recombinant], Plasma/Albumin-Free), a recombinant factor VIII product, for patients with hemophilia A for both the control and prevention of bleeding episodes and surgical prophylaxis.

22 Feb 2008

Different treatments for acute kidney failure often have similar outcomes

An analysis of studies examining treatments for acute kidney failure indicates that intermittent hemodialysis and continuous kidney replacement therapy appear to lead to similar clinical outcomes, including a similar risk of death, according to an article in the February 20 issue of JAMA: The Journal of the American Medical Association.

20 Feb 2008

Warning about deaths and serious reactions linked to blood thinning drug heparin

The Food and Drug Administration (FDA) in the United States says the production of a popular blood thinning drug has been halted temporarily after more than 300 reports of health problems associated with the drug.

13 Feb 2008